Utidelone in Third-line and Above Treatment of Small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2023-09-05
Target enrollment:
Participant gender:
Summary
SCLC has a very high degree of malignancy, and 60% to 70% of patients are diagnosed as
extensive stage. The median survival of patients with limited-stage disease is about 15-20
months, and the median OS of patients with extensive-stage disease is about 8-13 months, and
the 2-year and 5-year survival rates are about 5% and 1-2%, respectively. However, although
the initial treatment has a high effective rate, most patients relapse or progress within 1
year, and the effect of re-treatment is poor and the prognosis is poor. The effective rate of
SCLC second-line treatment is only 10-25%, and the median survival time is less than 6
months. After the third and fourth lines, there are almost no recognized treatment options.
Therefore, improving the second-line treatment of SCLC has always been a difficult clinical
problem, and new drugs are urgently needed to be explored. In small cell lung cancer, based
on phase II clinical trials, paclitaxel is currently recommended by NCCN guidelines for
subsequent systemic therapy in patients who relapse 6 months or less after initial therapy.
Utidelone (UTD1) is an epothilone derivative with a similar mechanism of action to taxanes,
but a completely different molecular structure.